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Abstract The role of rab33b, a Golgi-specific rab protein, was
investigated. Microinjection of rab33b mutants stabilised in the
GTP-specific state resulted in a marked inhibition of anterograde
transport within the Golgi and in the recycling of glycosyl-
transferases from the Golgi to the ER, respectively. A GST-
rab33b fusion protein stabilised in its GTP form was found to
interact by Western blotting or mass spectroscopy with Golgi
protein GM130 and rabaptin-5 and rabex-5, two rab effector
molecules thought to function exclusively in the endocytic
pathway. A similar binding was seen to rab1 but not to rab6,
both Golgi rabs. In contrast, rab5 was as expected, shown to bind
rabaptin-5 and rabex-5 as well as the endosomal effector protein
EEA1 but not GM130. No binding of EEA1 was seen to any of
the Golgi rabs. ß 2001 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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1. Introduction
The role of small GTPases belonging to the rab family in
membrane tra⁄cking has been investigated extensively. Of the
40 or so rab proteins identi¢ed biochemically to date, some
have been shown to actively regulate protein transport, both
in the exocytic and the endocytic pathway (for review, see
[1,2]). Several rab proteins have been mapped to the secretory
pathway and shown to promote various aspects of transport
and membrane biogenesis. Rab1, for example, was identi¢ed
¢rst in yeast as ypt1 [3,4]. It is involved in endoplasmic retic-
ulum (ER) to Golgi transport [5^7]. Rab6 localises to the
medial to trans Golgi and promotes recycling from the Golgi
to the ER [8^10]. The recently described rab33b is a novel rab
protein that localises to the medial Golgi [11] and is unknown
in its function and protein interactions.
Rabs serve as regulatory factors in the recruitment and
assembly of e¡ector molecules on membranes. Rab1 interacts
with p115 and GM130 [12^14]. Within the Golgi apparatus,
p115 and GM130 as well as giantin are examples of stacking
and tethering proteins that are thought to keep Golgi cister-
nae together or tether vesicles to acceptor Golgi membranes.
GM130 is found preferentially in the cis Golgi. It is bound to
Golgi membranes via GRASP65, a stacking protein, and both
GM130 and giantin have binding sites for p115 [15^21]. Rab6
interacts with rabkinesin-6 implicating it in the regulation of
motility and/or membrane extensions [10,22]. Rab5 has been
shown to interact with EEA1, rabaptin-5, rabaptin-5L and
rabex-5. These proteins play crucial roles in docking and fu-
sion of endosomal membranes [23^29]. Rab5 also regulates
the motility of endosomes through unknown protein interac-
tions [30]. The available data suggest that rab proteins asso-
ciated with the Golgi apparatus have relatively speci¢c sets of
e¡ector proteins.
In the present work, we tested the in vivo importance of
rab33b in the organisation of the Golgi apparatus and then
asked in vitro if rab33b displayed a unique or overlapping set
of interacting proteins when compared with rab1, rab6 and
rab5. We show by overexpression that rab33b and its GTP-
bound mutant play an important role in Golgi organisation
and retrograde transport. In a screen for interacting compo-
nents using mass spectroscopy and Western blotting, we
found that rab33b interacted in a GTP-speci¢c manner with
the Golgi protein GM130, and also with rabaptin-5 and ra-
bex-5, two proteins that until now have been thought to func-
tion exclusively in the endosomal pathway. We also found
that rab1 but not rab6 interacted with rabaptin-5 and ra-
bex-5. We suggest that overlapping combinatorial e¡ector
sets are assembled by Golgi-associated rabs.
2. Materials and methods
2.1. Antibodies
A⁄nity-puri¢ed monoclonal antibodies against rab33b have been
described previously [11]. Monoclonal antibodies against rab5, EEA1
and rabaptin-5 were from Transductions Laboratories (Lexington,
KY, USA). Polyclonal rabbit antibodies to GM130 were a gift from
Hiro Nakamura (Kanazava University, Kanazava, Japan). Polyclonal
rabbit antibodies to gp27 and the cytoplasmic domain of VSV-G
protein have been described previously [31,32]. Monoclonal antibodies
to the lumenal domain of VSV-G protein were a kind gift from Rai-
ner Pepperkok (EMBL, Germany). Polyclonal sheep anti-TGN46
antibodies were a gift from Vas Ponnambalam (University of Dundee,
Dundee, UK). Monoclonal mouse anti-myc antibodies were a kind
gift from Eric Karsenti (EMBL, Germany). Donkey anti-sheep HRP,
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goat anti-rabbit HRP, goat anti-mouse HRP, Cy3-conjugated donkey
anti-mouse and anti-rabbit IgG antibodies were from Dianova (Ham-
burg, Germany). Donkey anti-sheep IgG (Alexa 488), goat anti-mouse
IgG (Alexa 488) and goat anti-rabbit IgG (Alexa 488) antibodies were
from Molecular Probes (Leiden, The Netherlands).
2.2. cDNAs
Full-length cDNA encoding rab33bwt in pBluescript KS+ has been
described previously [11]. Constructs of rab33bQ92L and rab33bT47N
were generated by PCR-based mutagenesis [33]. The sequences of
ampli¢ed cDNA fragments were veri¢ed and cloned into pBluescript
KS+. Inserts were then ligated into pCMUIV [34] and pEYFP-C1
(Clontech, Heidelberg, Germany). Rab6wt in pCMUIV has been de-
scribed [8]. Rab5Q79L in pGEM-1 and rab1wt in pET-11d were kindly
provided by Marino Zerial (Max-Plank-Institut, Dresden, Germany).
PCR was performed to introduce £anking BamHI sites and an up-
stream Kozac consensus sequence, using rab5Q79L or rab1wt comple-
mentary sequences as templates. The PCR product of rab5Q79L was
cloned into pCMUIV for mammalian expression and the ORFs of
rab1wt, rab6wt and rab33bwt were cloned into pGEX-4T-3 for pro-
karyote expression of GST-rab fusion proteins. GST-rab5wt in
pGEX-5X-3 was kindly provided by Marino Zerial (Max-Plank-In-
stitut).
2.3. Cell culture
HeLa cells were cultured on 10 mm glass coverslips in Dulbecco’s
modi¢ed Eagle’s medium (DMEM) supplemented with 10% FCS
(PAA laboratories, Linz, Austria), 10 mM L-glutamine, penicillin
(100 U/ml) and streptomycin (100 Wg/ml) (Gibco, Eggenstein, Ger-
many). The stable HeLa cell lines expressing GalNAc-T2-GFP or
murine mannosidase II-VSV (Mann II) have been described [35,36].
For rab33bwt, rab33bQ92L and rab33bT47N in pEYFP-C1, 20 Wg pu-
ri¢ed plasmid were transfected into 10 cm Petri dishes and selected for
stable expression as described [37] with the modi¢cation that 3 weeks
post-transfection, cells were sorted using a £uorescent-activated cell
sorter (FACS) to select for YFP expression in the medium range.
Stable cell lines were grown as described above but with the addition
of 300 Wg/ml G418 (Gibco).
2.4. Microinjections and Cy3 Shiga-like toxin-B-fragment uptake
Puri¢ed plasmids were microinjected into cell nuclei with minor
modi¢cations of previous procedures [36]. DNA concentrations
ranged from 200 to 1000 ng/Wl for rab33b plasmids. pCMUIV plas-
mids encoding pSARA (Sar1pdn dominant negative mutant which
blocks ER exit [36]) or VSV-Gtso45-GFP were microinjected at a
DNA concentration of 200 ng/Wl. A coinjection marker was used,
70 kDa ¢xable Cascade blue dextran (Molecular Probes, Eugene,
OR, USA), at a concentration of 3.33 mg/ml. Cells were microinjected
at room temperature with plasmid encoding VSV-Gtso45-GFP protein
in the absence or presence of plasmid encoding rab33b, incubated at
39.5‡C for 6 h, and then shifted to the permissive temperature, 31.5‡C.
In experiments assessing the e¡ect of rab33b mutants on retrograde
tra⁄cking between the Golgi apparatus and ER, coverslips were
scratched to enclose a small area and all the cells within that area
microinjected. Cells were microinjected ¢rst with rab33b mutant at a
plasmid concentration of 1000 ng/Wl. After a 16 h expression period,
cells were then either incubated with Cy3-Shiga-like toxin (SLT)-B-
fragment as described [8] or microinjected a second time, with pSARA
plasmid. Coverslip cultures were incubated then for an additional 2 or
6 h and ¢xed in formaldehyde. Protein distributions were quanti¢ed
for an average of 10 cells per condition.
2.5. Immuno£uorescence
Routinely, cells were ¢xed in 3.5% formaldehyde in PBS for 15 min,
permeabilised and blocked in 0.1% saponin/0.2% gelatin in phosphate-
bu¡ered saline (SG/PBS) for 20 min and then incubated 1 h with the
primary antibody. The cells were washed three times with SG/PBS
and incubated for 20 min with the secondary antibody. Cells were
again washed three times in PBS and mounted on microscope slides
in Mowiol. For visualisation of TGN46, Mann II and VSV-G, cells
were permeabilised in 0.1% Triton X-100 rather than saponin.
2.6. Bovine brain cytosol, HeLa extract and rat liver Golgi extract
Bovine brain cytosol was prepared as described [24]. For HeLa
extract, S-HeLa cells were grown in spinner £asks. Cells were har-
vested and pelleted at 3000 rpm using a Sorvall GS-3 rotor for 10 min
at 4‡C. Cells were washed in PBS and pelleted twice. Cells were
washed in 20 mM HEPES, 250 mM NaCl, 5 mM MgCl2, 1 mM
dithiothreitol (DTT), pH 7.5 and re-pelleted. Cells were ¢nally resus-
pended in extraction bu¡er (20 mM HEPES, 250 mM NaCl, 5 mM
MgCl2, 1 mM DTT, 1% Triton X-100, pH 7.5) and passed through a
ball bearing homogeniser 20 times. The lysate was cleared by ultra-
centrifugation at 45 000 rpm for 60 min at 4‡C using a TLA-45 rotor
(Beckman). Extracts were then snap frozen in liquid nitrogen and
stored at 380‡C. Before incubation with GST fusion protein, the
extract was centrifuged at 23 100Ug for 30 min at 4‡C. Typically
the protein concentration was 25^30 mg/ml. Rat liver Golgi mem-
branes and rat liver cytosol were prepared as described [38], snap
frozen in liquid nitrogen and stored at 380‡C. For Golgi extract,
rat liver Golgi membranes were thawed and spun at 23 100Ug for
15 min at 4‡C. Pelleted membranes were resuspended in extraction
bu¡er (as above) and then incubated at 4‡C for 1 h rotating. Typically
the protein concentration was 5 mg/ml. The extract was spun at
1000Ug for 5 min at 4‡C before incubating with GST fusion proteins.
2.7. GST-rab fusion protein chromatography and immunoprecipitations
GST-rab fusion proteins and GST were expressed in Escherichia
coli and puri¢ed according to the manufacturer’s instructions (Phar-
macia, Uppsala, Sweden). GST-rab fusion proteins were used as baits
to identify nucleotide-speci¢c interacting components as described
[24,39]. In short, GST-rab proteins stabilised in the GTP-bound or
GDP-bound state were incubated with bovine brain cytosol, HeLa
extract or rat liver Golgi extract. Interacting proteins were eluted as
described [24,39]. Eluates were then subjected to sodium dodecyl sul-
phate^polyacrylamide gel electrophoresis (SDS^PAGE) and separated
proteins were visualised by silver or Coomassie staining or transferred
to nitrocellulose (Schleicher and Schuell, Dassel, Germany) for West-
ern blotting using the ECL method (Amersham Life Science, Amer-
sham, UK) and X-Omat XAR5 ¢lm (Eastman Kodak Co., Rochester,
NY, USA).
For immunoprecipitation anti-rabaptin-5 or anti-myc antibodies
were coupled to protein G Dynabeads (Dynal, Hamburg, Germany),
washed in PBS and incubated with HeLa extract for 1 h at 4‡C
rotating. The beads were washed three times with PBS containing
0.1% Triton X-100 and then incubated in SDS^PAGE Laemmli sam-
ple bu¡er for 15 min at room temperature. The beads were removed
from the bu¡er and the sample subjected to SDS^PAGE followed by
Western blotting.
2.8. Identi¢cation of interacting factors
Gel proteolytic cleavage was performed automatically in the ‘Pro-
gest’ as described [40,41] (Genomic Solutions Cambridge, UK). Pep-
tides were analysed on a Bruker REFLEX matrix-assisted laser de-
sorption ionisation time-of-£ight mass spectrometer (Bruker Analytik,
Bremen, Germany) equipped with a 337 nm N2 laser and the grid-less
delayed extraction option [42]. The peptide mass maps were recorded
with mass resolution up to 15 000 and mass accuracy below 50 ppm.
The products of trypsin autolysis were used as internal calibrants. A
list of tryptic peptide masses generated from the mass spectrum was
entered into the programme PeptideSearch [40] and used to screen a
non-redundant sequence database (NRDB) maintained at the Euro-
pean Bioinformatics Institute in Cambridge, UK (ftp://ftp.ebi.ac.uk/
pub/databases/PeptideSearch/).
3. Results
3.1. The Golgi-speci¢c rab33b is involved in retrograde
transport
Rab33b was originally identi¢ed in a general screen for
small GTPases and was shown to localise to the medial Golgi
apparatus at the ultrastructural level by immunoperoxidase
labelling of KB cells (human pharyngeal carcinoma cells)
[11]. Northern blotting revealed the expression of rab33b in
most tissues and commonly used cell lines including HeLa
cells. Indirect immuno£uorescence revealed a compact juxta-
nuclear staining pattern in KB cells consistent with an exclu-
sive Golgi localisation. To con¢rm Golgi localisation in HeLa
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cells, used throughout this study, we stained for endogenous
rab33b and compared this to the Golgi resident proteins,
gp27(p24Q3) (cis Golgi network/cis) [31], mannosidase II
(Mann II) (medial/trans) [35] and TGN46 (trans Golgi net-
work) [43]. As can be seen in Fig. 1, the stainings of endog-
enous rab33b (Fig. 1A) and gp27 (Fig. 1B) showed partial
overlap (Fig. 1C) in the juxtanuclear area. Similarly, endoge-
nous rab33b (Fig. 1G) revealed partial overlap (Fig. 1I) with
endogenous TGN46 (Fig. 1H) whereas an almost complete
colocalisation (Fig. 1F) was observed between endogenous
rab33b (Fig. 1D) and Mann II (Fig. 1E) stably expressed in
HeLa cells [35]. To rule out that rab33b was also localised
outside the secretory pathway, a possibility raised by occa-
sional scattered punctate structure as shown in Fig. 1D, G,
we constructed a YFP-rab33b fusion protein and expressed
this stably in HeLa cells. Pronounced juxtanuclear £uores-
cence for YFP-rab33b was observed in these cells with an
additional faint perinuclear staining pattern consistent with
an ER localisation of the rab protein (Fig. 1J). When overex-
pressed, rab33b had no tendency to accumulate in punctate,
non-Golgi-like structures in the cytoplasm (Fig. 1J and also
Fig. 3C, D). Golgi protein distribution was normal in the low
expressing cells (Fig. 1J) as marked by GalT (data not
shown).
As an initial test of the role of rab33b in the secretory
pathway, we examined its e¡ect on the anterograde transport
of a temperature-sensitive mutant of the G protein of vesicu-
lar stomatitis virus (VSV) fused to GFP via its cytoplasmic
domain, VSV-Gtso45-GFP [44]. Plasmid DNA encoding the
VSV-Gtso45-GFP was microinjected into HeLa cells together
with DNA encoding mutants of rab33b restricted in either the
GDP (rab33bT47N)- or the GTP (rab33bQ92L)-bound state.
Cells were then incubated at the restrictive temperature,
39.5‡C, to accumulate the VSV-Gtso45-GFP in the ER for 6 h
and then transferred to 31.5‡C to release VSV-Gtso45-GFP
from the ER. The total GFP £uorescence was compared to
the cell surface staining of VSV-Gtso45-GFP using a monoclon-
al antibody (mAb) to the lumenal domain of VSV-G in cells
¢xed and incubated with mAb and red £uorescent secondary
antibody before permeabilisation. Cells were then permeabi-
Fig. 1. Localisation comparisons of rab33b and Golgi markers. HeLa cells were ¢xed, permeabilised and stained for rab33b, gp27 (cis/CGN),
Mann II-VSV (medial) and TGN46 (TGN). Note that rab33b does give the most extensive colocalisation with Mann II but less with gp27 and
TGN46. A: Endogenous rab33b. B: Endogenous gp27. C: Overlay of rab33b and gp27. D: Endogenous rab33b. E: Mann II-VSV. F: Overlay
of rab33b and Mann II-VSV. G: Endogenous rab33b. H: Endogenous TGN46. I: Overlay of rab33b and TGN46. J: YFP-rab33bwt stably ex-
pressed in HeLa cells. CP, FP and IP : Higher magni¢cation views of the boxed areas in C, F and I respectively. Scale bars represent 10 Wm.
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lised for incubation with mAb directed against rab33b fol-
lowed by blue £uorescent secondary antibody. This subse-
quent mAb incubation was required to identify the level of
expression of the rab33b mutants. Only in cells exhibiting a
high level of rab33b expression were phenotypic e¡ects on
secretion observed. Low level expression had no e¡ect on
VSV-Gtso45 transport to the cell surface (data not shown).
Before transfer to permissive temperature VSV-Gtso45-GFP
was exclusively seen in the ER and nuclear envelope, a char-
acteristic extension of the ER (e.g. Fig. 2B), with little or no
surface staining (Fig. 2A). Following 1 h at permissive tem-
perature, only relatively small amounts of ER staining could
be seen. Most of the VSV-Gtso45-GFP was seen instead in the
juxtanuclear region of the Golgi apparatus (Fig. 2D) and at
the cell surface (Fig. 2C and D). Upon high level expression of
rab33bQ92L, very little if any VSV-Gtso45-GFP could be de-
tected at the cell surface (Fig. 2E). Instead, the main portion
of the fusion protein appeared arrested in the juxtanuclear
region of the cell, Golgi apparatus and/or intermediate com-
partment. In contrast, high level expression of rab33bT47N had
little if any visible e¡ect on VSV-Gtso45-GFP transport to the
cell surface (Fig. 2G and H). We presume that the concen-
Fig. 2. GTP-bound rab33b inhibits VSV-G protein secretion. HeLa cells were microinjected with plasmid DNA encoding VSV-Gtso45-GFP, ei-
ther alone or together with a plasmid DNA encoding the constitutively active mutant rab33bQ92L or the inactive mutant rab33bT27N. Cells were
incubated at 39.5‡C for 6 h and then chased for 1 h at 31.5‡C before ¢xing. VSV-G transport to plasma membrane was examined by staining
for the lumenal domain of VSV-G protein. A and B: Before chasing at 31.5‡C VSV-G is ER localised (surface staining and GFP £uorescence,
respectively). C and D: After 1 h chase VSV-G is found both in the Golgi and on the surface. E and F: Upon coinjection of rab33bQ92L,
VSV-G is transported to the Golgi but does not reach the plasma membrane whereas rab33bT47N has little, if any, e¡ect on the transport (G
and H). I: Quanti¢cation analysis showed that little if any VSV-G is found on the cell surface when co-expressing rab33bQ92L. Scale bar repre-
sents 10 Wm.
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trated £uorescence in the Fig. 2G cell surface image re£ects
either bleed through between £uorescence channels or anti-
body leakage from the cell surface staining procedure. The
rab33bQ92L-speci¢c inhibition of VSV-Gtso45-GFP transport
to the cell surface was con¢rmed through quanti¢cation
when compared to either VSV-Gtso45-GFP alone or with
rab33bT47N (see Fig. 2I). These data suggest that rab33b is
needed for anterograde transport of VSV-Gtso45-GFP through
the Golgi stack or subsequent downstream transport from the
Golgi to the cell surface. This e¡ect may be either direct or
indirect. High level overexpression of the other known cister-
nal Golgi rab, rab6, blocks VSV-Gtso45 transport through the
Golgi indirectly by disrupting the structural organisation of
the Golgi apparatus; Golgi resident enzymes relocate to the
ER [9].
To ask if rab33b also redistributed Golgi resident enzymes
when overexpressed at the high levels required to inhibit VSV-
Gtso45 transport to the cell surface, we tested the e¡ect of these
expression levels on the distribution of Golgi stack resident
N-acetylgalactosaminyltransferase-2 fused to GFP (GalNAc-
T2-GFP) [36]. HeLa cells stably expressing GalNAc-T2-GFP
were microinjected with plasmid DNA encoding the di¡erent
rab33b mutants or wild-type rab33b to achieve a high level of
expression as assayed by antibody staining for rab33b. As can
be seen in Fig. 3A, microinjection of rab33bQ92L caused ER
accumulation as indicated here by the high level of cytoplas-
Fig. 2 (Continued).
Fig. 3. Overexpression of GTP-bound rab33b relocalises Golgi resident enzymes to the ER. HeLa cells stably transfected with GalNAc-T2-
GFP were microinjected with plasmids encoding the constitutively active mutant rab33bQ92L or the inactive mutant rab33bT47N. After 6 h or 16
h incubation at 37‡C cells were ¢xed, stained for rab33b, and the localisation of GalNAc-T2 examined. A: Cells overexpressing rab33bQ92L (as-
terisks) showed an ER localisation of GalNAc-T2. B: Rab33bT47N expressing cells (asterisks) still had a compact, juxtanuclear Golgi £uores-
cence even after 16 h. C and D: HeLa cells stably expressing YFP-rab33b mutants (rab33bQ92L and rab33bT47N respectively) show predomi-
nantly juxtanuclear localisation of the protein.
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mic GalNAc-T2-GFP relative to non-injected cells whereas
even with longer expression, 16 h versus 6 h, rab33bT47N did
not (Fig. 3B). At su⁄ciently high expression, rab33b wild-type
also produced ER accumulation of GalNAc-T2 (data not
shown). Consistent with this, transient transfection to produce
high level expression of either rab33b mutant into HeLa cells
stably expressing Mann II revealed similar phenotypes (data
not shown). Stable, low level expression of rab33b mutants
fused to YFP in HeLa cells (Fig. 3C, D) did not cause any
signi¢cant relocation of Golgi enzymes (data not shown)
again indicating that high level expression is required to dis-
rupt the normal cell phenotype. These data show that rab33b
regulates Golgi organisation. Further they suggest that rab33b
a¡ects anterograde transport indirectly rather than directly.
Comparative microinjection studies with rab6 mutants sug-
gested that on a mass basis rab33b exerted less e¡ect on Golgi
to ER relocation than did rab6 (data not shown).
The GDP-bound mutant of rab6 selectively inhibits COPI-
independent protein recycling between the Golgi apparatus
and ER while having minimal e¡ect on the juxtanuclear or-
ganisation of the Golgi apparatus [8]. Similarly, the GDP-
bound mutant of rab33b (rab33bT47N) had no e¡ect on the
distribution of Golgi resident enzymes. To test the e¡ect of
rab33bT47N on retrograde tra⁄cking, we ¢rst expressed the
mutant for 16 h in GalNAcT2-GFP HeLa cells and then in-
troduced an ER exit block. As shown in Fig. 4A, the pSARA-
encoded Sar1pdn ER exit block (coinjection marker, Cascade
blue dextran, not shown) produced an ER accumulation of
GalNAc-T2-GFP in cells expressing Sar1pdn alone (e.g. aster-
isk only). In cells expressing both Sar1pdn (coinjection marker
not shown) and rab33bT47N (antibody staining not shown) the
GalNAc-T2-GFP distribution remained juxtanuclear (e.g. as-
terisk and arrow). In the alternative test, we incubated HeLa
cells with Cy3-SLT-B-fragment, a known substrate of the
COPI-independent Golgi recycling pathway [8,10]. As shown
following a 6 h incubation, Cy3-SLT-B-fragment £uorescence
accumulated at least partially over the cytoplasm in cells not
expressing rab33bT47N (Fig. 4B, arrowheads) while in cells
expressing rab33bT47N (antibody staining not shown) typically
no cytoplasmic £uorescence was observed (Fig. 4B, arrows).
Please note that although the extent of Cy3-SLT-B-fragment
clearance from the Golgi apparatus in this experiment was
low relative to that reported previously [8], the di¡erences
plus and minus rab33bT47N are nevertheless su⁄cient to indi-
cate a rab-dependent e¡ect. Results were quanti¢ed by scoring
the e¡ect of rab33bT47N either on the distribution of GalNAc-
T2 in Sar1pdn expressing cells or on the distribution of Cy3-
SLT-B-fragment. In both cases, the quanti¢cation revealed
that rab33bT47N inhibited Golgi to ER tra⁄cking (Fig. 4C).
We conclude that rab33b is a switch for retrograde tra⁄cking
between the ER and Golgi apparatus with rab33bQ92L and
wild-type being in the positive state while rab33bT47N is in
the negative state.
3.2. Identi¢cation of interacting components
Having established that rab33b is functionally signi¢cant
with respect to the Golgi apparatus, we proceeded to identify
molecular machinery components with which it interacted.
Using the GST fusion protein approach established by Zerial
and co-workers, we screened by two procedures for proteins,
which interacted speci¢cally with the GTP-bound form of
rab33b but not with the GDP-bound form. In the ¢rst pro-
Fig. 4. GDP-bound rab33b inhibits Golgi to ER transport.
A: HeLa cells stably expressing GalNAc-T2-GFP where microinjected
with a plasmid encoding rab33bT47N mutant (arrow), incubated at
37‡C for 16 h and then microinjected with a plasmid encoding the
Sar1pdn mutant in the presence of Cascade blue dextran coinjection
marker (asterisks). Cells were incubated at 37‡C for another 6 h
and then ¢xed and stained for rab33b. As can be seen, Sar1pdn in-
hibited ER export when injected alone and thereby caused accumu-
lation of GalNAc-T2 in the ER. Upon co-expression with
rab33bT47N, Golgi to ER transport was blocked (arrow) as indicated
by the lack of GalNAc-T2 relocalisation. B: HeLa cells were micro-
injected with a plasmid encoding rab33bT47N mutant (arrows) and
incubated at 37‡C for 16 h. Cells were then treated with Cy3-ST-B-
fragment at 4‡C for 30 min, cultured at 37‡C for 6 h, and subse-
quently ¢xed and stained for rab33b. Transport of the B-fragment
from Golgi to ER was blocked upon overexpression of rab33bT47N
(arrow) whereas cells not expressing the mutant did show normal
ER and Golgi localisation of the B-fragment (arrowheads).
C: Quanti¢cation of the e¡ect of rab33bT47N on transport of B-frag-
ment or GalNAc-T2 to the ER. Control cells (3) or cells pre-ex-
pressing rab33bT47N (+) were either incubated with B-fragment at
4‡C and then chased for 2 h or 6 h at 37‡C, or microinjected with
pSARA and incubated at 37‡C for 6 h. Cells were ¢xed and stained
for rab33b and distribution of B-fragment or GalNAc-T2 scored.
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cedure, components exhibiting speci¢city for interactions with
two a⁄nity columns, stabilised with GTPQS or with GDP,
were identi¢ed by mass spectroscopy, and in the second by
Western blotting. In initial mass spectrometry experiments,
cytosols were prepared from bovine brain, and interacting
components eluted with EDTA and separated by SDS^
PAGE. Candidate components interacting speci¢cally with
the GTP-bound form of rab33b were then digested with tryp-
sin, eluted from the gel and analysed by mass spectrometry.
The most prominent band was that of a protein migrating at
an apparent molecular weight of a 40 kDa. This protein was
identi¢ed as a brain-speci¢c aldolase. Of higher molecular
weight proteins, two were identi¢ed as rabaptin-5 and ra-
bex-5 (Fig. 5A). Note that whereas rabaptin-5 was readily
visible by silver staining rabex-5 was not but could be faintly
stained using Coomassie blue when loading a greater amount
of proteins (data not shown). A total of 33 and 24 peptides
were matched with high accuracy by mass spectrometry ¢n-
Fig. 5. Rab33b interacts with several factors in a GTP-speci¢c manner. GST-rab33b columns stabilised in the GTP-bound or GDP-bound form
were incubated with bovine brain cytosol, HeLa or rat liver Golgi extracts. A: Retained proteins from bovine brain cytosol were eluted from
the columns, run on SDS^PAGE gels and silver stained. Several bands speci¢c for the GTP-bound form of rab33b were sequenced and identi-
¢ed as rabaptin-5, rabex-5 and a brain-speci¢c aldolase. B: Results from the sequencing were con¢rmed by Western blotting. Both bovine ra-
baptin-5 and rabex-5 interact speci¢cally with the GTP-bound form of rab33b. C: Immunoprecipitation from HeLa extract using anti-rabaptin-
5 antibodies brought down rab33b whereas the mock antibodies did not, as shown by Western blotting. D: HeLa extract was incubated with
rab33b, rab1, rab5 and rab6. Retained proteins were eluted, run on SDS^PAGE for Western blotting and the membrane probed with di¡erent
antibodies. EEA1 interacted speci¢cally to the GTP-bound form of rab5 but to none of the Golgi rabs. Rabaptin-5 interacted speci¢cally to
the GTP-bound form of rab1, rab5 and rab33b and GM130 interacted with rab1, rab6 and rab33b but not with rab5. E: Rab columns were
incubated with rat liver Golgi extract and eluted components run on SDS^PAGE for Western blotting and the membrane probed for GM130.
Again, GM130 was found only on rab1, rab6 and rab33b columns but not on the rab5 columns.
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ger-printing to rabaptin-5 and rabex-5, respectively. That the
higher molecular weight protein was indeed rabaptin-5 and
not rabaptin-4 [45] was evident from one of the peptides in
the mixture covering a region speci¢c only for rabaptin-5
(data not shown). Rabaptin-5 and rabex-5 interaction with
rab33b in its GTP-bound form was con¢rmed by Western
blotting using speci¢c antibodies (Fig. 5B).
The identi¢cation of aldolase, rabaptin-5 and rabex-5 as
interacting components prompted us to examine if similar
interacting proteins could be detected using other sources
than bovine brain cytosol. Detergent extracts from HeLa cells
were prepared and tested for interactions by an independent
assay. Co-immunoprecipitation of rab33b and rabaptin-5 was
performed using antibodies against rabaptin-5 (Fig. 5C). We
then passed HeLa extracts over GST-rab33b columns as be-
fore. In those experiments we did not see a GTP-speci¢c band
at 40 kDa. For comparison, GTP- and GDP-stabilised col-
umns of rab1, rab5 and rab6 were also examined. As shown in
Fig. 5C, a GTP-speci¢c interaction of the endosomal rab5
e¡ector, EEA1, could only be seen with rab5. In contrast,
rabaptin-5 was seen interacting speci¢cally with rab1, rab5
and rab33b but not with rab6.
After having found that rabaptin-5 and rabex-5 interacted
with Golgi rab proteins we decided to examine if peripheral
proteins, implicated in the tethering of vesicles or stacking of
Golgi membranes such as GM130, would also interact. As
shown by Western blotting in Fig. 5D and E, GM130 inter-
acted speci¢cally with the GTP-bound form of rab33b, rab1
and rab6. GM130 was not retained on rab5 columns. That
EEA1 but not GM130 was shown interacting with the GTP-
bound form of rab5 suggests that indeed, the observed inter-
actions were of a highly speci¢c nature. To further support
this conclusion, we assessed the e¡ectiveness of the GTPQS
procedure in producing nucleotide exchange from GDP to
GTP to generate a fully GTP-bound rab column. This is im-
portant because the presence of GDP-bound rab reduces col-
umn capacity for binding GTP state-speci¢c rab e¡ectors. Our
GDP rab probe was rab GDP dissociation inhibitor, rab-
GDI. Rab-GDI is a general rab e¡ector that binds to the
GDP- not GTP-bound form of rabs [46]. The binding of
rab-GDI to each column was then detected by Western blot-
ting. No rab-GDI could be detected in the eluant from the
GTP-stabilised columns of rab33b or rab5 but only in the
eluant from the respective GDP-stabilised columns. On the
other hand some rab-GDI was seen binding to the GTP-sta-
bilised columns of rab1 and rab6 suggesting that these two
rab proteins had not exchanged from GDP to GTP as well as
rab5 and rab33b (data not shown). Hence the results from the
rab1 and rab6 GTP-stabilised columns might have underesti-
mated nucleotide-speci¢c binding of interacting components.
4. Discussion
Our experiments had two goals. First, to establish that
rab33b, a novel Golgi-associated rab localised to medial cis-
ternae was of functional signi¢cance with respect to the or-
ganelle. Second, to ask if rab33b was associated with a unique
or overlapping set of interacting proteins, i.e. putative e¡ector
molecules. The current consensus is that each rab protein has
a relatively speci¢c set of e¡ectors. We report that rab33b is
involved in retrograde transport between the Golgi apparatus
and ER. Likely its e¡ect on anterograde transport to the cell
surface is an indirect consequence of its involvement in retro-
grade transport. The regulatory e¡ect of rab33b seems to
occur through an overlapping, combinatorial set of protein
interactions. We ¢nd that rabaptin-5, rabex-5, GM130 inter-
acted speci¢cally with the GTP-bound form of rab33b. These
in vitro interactions overlapped at least in part. We found
GM130, rabaptin-5, rabex-5 interacted with rab1, involved
in ER to Golgi transport, GM130 with rab6, localised to
medial to trans cisterna, and rabaptin-5 and rabex-5 with
rab5, the endosomal rab from which rabaptin-5 and rabex-5
derive their names. The in vitro discovery of novel rabaptin-5
and rabex-5 interactions clearly validates our initial choice of
the relatively unbiased procedure of mass spectroscopy iden-
ti¢cation of interacting components versus Western blotting.
Our in vitro observations challenge the current dogma of how
rabs function and clearly indicate the need for further mass
spectroscopic probing of rab interactions.
Rab33b was found to partially colocalise with the CGN/cis
marker gp27 and the TGN marker TGN46 but the best over-
lap was with the medial Golgi marker Mann II. This is con-
sistent with previously published data [11]. Overexpression of
the constitutively active mutant of rab33b caused the reloca-
tion of Golgi resident enzymes to the ER. The inactive mutant
prevented or slowed down the recycling. This is shown by the
fact that expression of the rab33bT47N mutant blocks Gal-
NAc-T2 in the Golgi in majority of cells when ER export is
inhibited using Sar1pdn. A similar block was seen for retro-
grade movement of SLT-B-fragment upon overexpression of
rab33bT47N. These data strongly suggest that rab33b has a
regulatory role in retrograde transport and provide an expla-
nation for the inhibition of VSV-G protein transport from the
ER to the cell surface. Similar results were obtained by Girod
et al. [8] using rab6T27N although rab33b seems to have some-
what less drastic e¡ects. Longer expression times were needed
for the relocation of Golgi enzymes to the ER using the con-
stitutively active mutant of rab33b. Conversely, a complete
inhibition of Golgi to ER transport was not observed upon
expression of rab33bT47N. A possible interpretation of these
results is that rab33b acts upstream (medial) of rab6 (trans) in
regulating Golgi to ER COPI-independent recycling. As sug-
gested previously [47], a likely route for Golgi to ER recycling
is through the direct but regulated fusion between cisternal
remnants and the ER at the trans side of the Golgi stack.
This is made possible by the juxtaposition of these two com-
partments [48]. Indeed, components of the trans cisternae ap-
pear to redistribute faster than those of the medial cisternae
making this scenario a likely one [49].
Having established a functional importance of rab33b, we
then ‘¢shed’ for interacting proteins. Using a GST fusion
protein approach we found an interesting set of components
that interacted with rab33b in a GTP-speci¢c manner. Out of
those, three proteins were sequenced as rabaptin-5, rabex-5
and a brain-speci¢c aldolase by mass spectrometry. Rabap-
tin-5 and rabex-5 have so far been implicated as speci¢c ef-
fectors in the endocytic pathway, being necessary for fusion of
early endosomes [25,26,29]. It was therefore a surprise to ¢nd
them interacting with rab33b, which shows little if any ten-
dency to localise to endosomes. Moreover, this suggested to
us that rab33b, rabaptin-5 and rabex-5 might be involved in
the docking and fusion of vesicles in the Golgi apparatus or in
homotypic fusion events between Golgi membranes/cisternae.
We then probed, by Western blotting, for interacting Golgi
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proteins in HeLa and rat liver Golgi extracts and found that
the tethering/stacking protein GM130 was also retained on
the GST-rab33b fusion protein columns in a GTP-speci¢c
manner. Preliminary experiments also suggest that GRASP65
interacts with rab33b (work in progress). Upon Western blot-
ting comparisons with other Golgi localised rab proteins as
well as with the endosomal rab5, we found that rab1 bound
essentially the same factors as rab33b and neither bound
EEA1, an endosomal protein known to interact with rab5
[24]. Recently, Weide et al. [14] and Moyer et al. [13] both
identi¢ed GM130 as an e¡ector of rab1 and in addition
Moyer et al. have shown that GRASP65 interacts with
rab1. Contrary to our data, Weide et al. failed to ¢nd an
interaction between GM130 and rab6. We found that the
interaction of GM130 with the GTPQS-stabilised rab6 column
was weak. Most likely this was due to a relatively poor nu-
cleotide exchange in vitro. Such a technical limitation may
also have a¡ected the data of Weide et al. We would like to
suggest that GM130, rabaptin-5 and rabex-5 are all e¡ectors
of rab33b as well as rab1. This raises the interesting possibility
that rab proteins have overlapping combinatorial e¡ector sets.
Balch and colleagues [13] have proposed on the basis of in
vitro assays with rab1 that the same rab protein can interact
with di¡erent e¡ectors at donor and acceptor membranes.
Our ¢ndings increase the range of combinations to be consid-
ered between rab proteins and e¡ector molecules.
In conclusion, we show that rab33b has a role in regulating
retrograde tra⁄c between the Golgi apparatus and ER. We
¢nd that rab33b interacts in a nucleotide-speci¢c manner with
a putative e¡ector set that includes overlapping components
used by rab1 and the endosomal rab5. Our work also illus-
trates the need for unbiased identi¢cation procedures such as
systematic mass spectroscopy analysis if we are to know the
full set of rab protein interactions.
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